UNSPSC 51111625: Azacitidine

This classification denotes a pyrimidine antagonist with the molecular formula C8H12N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M801H13NRU, chemically known as 1,3,5-triazin-2 (1h)-one, 4-amino-1-.beta.-d-ribofuranosyl- but generally known as azacitidine, which bears US NIH Compound Identifier 1805. European Medicines Agency schedules Azacitidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05624MIG.

UNSPSC 51111625 Azacitidine is a Commodity code covering procurement of this chemotherapy agent by state and local health systems, corrections departments, and public hospital networks. State and local buyers source azacitidine primarily for oncology treatment protocols in public hospitals and prison medical services, where it is used to treat myelodysplastic syndromes and certain leukemias. Purchasing bodies include state departments of health, county hospital systems, municipal health departments, and state and federal corrections agencies operating public medical facilities. Procurement typically occurs through RFPs issued by hospital pharmacy departments or centralized state health procurement offices, often leveraging group purchasing organizations (GPOs) or state pharmaceutical cooperative purchasing agreements to negotiate volume pricing and reduce unit cost across multiple facilities.

The source provides no recent state and local contract opportunities under this code, leaving geographic spread and recent solicitation activity unclear. Without documented recent RFPs, RFQs, or ITBs naming azacitidine procurement, the current market activity and response patterns cannot be characterized. Firms pursuing this code should monitor state health department procurement notices, GPO contract awards, and state prison system medical supply solicitations to identify when azacitidine demand materializes as formal purchasing activity.